A trial of strength

Peter McIntyre

Patients, doctors, academic researchers and the World Health Organization all want industry to be a lot more open about the drugs they are trialling. The industry is pleading commercial confidentiality. The two sides are locked in an argument over the requirements of a proposed WHO clinical trials registry. The question is: who will blink first?

Download full article

Be the first to comment

Leave a Reply

Your email address will not be published.